Danaher Corporation reported stronger-than-expected Q2 2026 earnings and revenue, driven by its Life Sciences segment, with EPS of $1.94 and revenue of $6.27 billion beating estimates. However, the stock fell nearly 12% in premarket trading due to investor concerns over weaker-than-expected biotech revenue and soft bioprocessing sales. Despite raising its adjusted profit forecast for 2026, Danaher trimmed its core revenue growth outlook, causing mixed market sentiment. The company maintains a stable financial position with a P/E ratio of 30.99 and a current ratio of 1.65, reflecting investor focus on future growth prospects.
Danaher Corporation reported a 60% year-over-year increase in Q2 2026 net earnings to $870 million, driven by strong core growth and the early completion of its Masimo acquisition. Revenues rose 5.5% to $6.3 billion, with adjusted earnings per share ...
Wall Street is preparing for a volatile week with major earnings reports from Big Tech companies like Alphabet and Tesla, which are seen as key tests for the AI-driven market rally. Over 70 S&P 500 companies, including IBM, Intel, and American Expres...
